Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.38 |
| ▸ | AMY2A | P04746 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | FGF1 | P05230 | 2/20 | 0.33 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.31 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22460849 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL18343942 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL7151354 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL15925201 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL10360872 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL313178 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL7154448 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL12013749 | 0.87 | LGALS8 (0.42) | LGALS8AMY2ALGALS3FGF1LGALS9 | |
| SCHEMBL20374903 | 0.81 | LGALS8 (0.47) | LGALS8LGALS3FGF1GAA | |
| SCHEMBL13758175 | 0.81 | LGALS8 (0.47) | LGALS8AMY2ALGALS3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281601-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | XDH, PON1, GLS | LGALS8 175/4885AMY2A 511/4885LGALS3 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.